ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- HER2 Positive Metastatic Breast Cancer
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: One single arm, open label with intravenous infusion of ARX788Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
A Global, Single Arm, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens. The ARX788 will be administered every 4 weeks (Q4W) intravenous (IV) infusion.
A Global, Single Arm, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens. The ARX788 will be administered every 4 weeks (Q4W) intravenous (IV) infusion.
Tracking Information
- NCT #
- NCT04829604
- Collaborators
- Not Provided
- Investigators
- Study Director: Ambrx Ambrx, Inc.
Get Well Soon